Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis
US11613580B2 · kind B2 · utility
0Cited by
1References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2017 |
| Grant date | Mar 28, 2023 |
| Priority date | — |
| Expiry date | Dec 4, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present disclosure relates to the use of anti-PAD4 autoantibodies as a clinical biomarker for rheumatoid arthritis (RA) treatment. The disclosure further provides an assay to detect anti-PAD4 autoantibodies, assay kits for the detection of anti-PAD4 autoantibodies, as well as computer implemented diagnostic methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.